Compare · MDT vs VRAY
MDT vs VRAY
Side-by-side comparison of Medtronic plc. (MDT) and ViewRay Inc. (VRAY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and VRAY operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $94.98B, about 130.7x VRAY ($726.7M).
- MDT has hit the wire 12 times in the past 4 weeks while VRAY has been quiet.
- MDT has more recent analyst coverage (25 ratings vs 9 for VRAY).
- Company
- Medtronic plc.
- ViewRay Inc.
- Price
- $73.97+0.20%
- $0.03-39.95%
- Market cap
- $94.98B
- $726.7M
- 1M return
- -8.67%
- -
- 1Y return
- -11.66%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 9
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
ViewRay Inc.
ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, Taiwan, the United Kingdom, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
Latest MDT
- SVP, Chief HR Officer Walter Matthew R. converted options into 9,149 units of Ordinary Shares, increasing direct ownership by 28% to 41,529 units (SEC Form 4)
- EVP & Pres Neuroscience Wall Brett A. converted options into 26,907 units of Ordinary Shares, increasing direct ownership by 49% to 82,183 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey converted options into 94,963 units of Ordinary Shares, increasing direct ownership by 38% to 343,099 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael converted options into 18,994 units of Ordinary Shares, increasing direct ownership by 37% to 70,593 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip converted options into 15,195 units of Ordinary Shares, increasing direct ownership by 46% to 48,233 units (SEC Form 4)
- Chief Accounting Officer Blomquist Denise L. converted options into 1,712 units of Ordinary Shares, increasing direct ownership by 13% to 14,974 units (SEC Form 4)
- SEC Form SD filed by Medtronic plc.
- Goldman resumed coverage on Medtronic with a new price target
- Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain
- Medtronic plc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest VRAY
- SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)
- SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)
- SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)
- NUBURU Appoints Brian Knaley as new CEO
- SEC Form 25-NSE filed by ViewRay Inc.
- ViewRay Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form NT 10-Q filed by ViewRay Inc.
- SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)
- SEC Form 4 filed by Shah Sanket
- SEC Form 4 filed by Podbelski Adam Andrew